Onconetix, Inc

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Onconetix, Inc and other ETFs, options, and stocks.

About ONCO

Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company was founded in October 2018 and is headquartered in Cincinnati, OH. 

CEO
Karina M. Fedasz
CEOKarina M. Fedasz
Employees
7
Employees7
Headquarters
Cincinnati, Ohio
HeadquartersCincinnati, Ohio
Founded
2018
Founded2018
Employees
7
Employees7

ONCO Key Statistics

Market cap
2.43M
Market cap2.43M
Price-Earnings ratio
-0.01
Price-Earnings ratio-0.01
Dividend yield
Dividend yield
Average volume
62.22K
Average volume62.22K
High today
$1.56
High today$1.56
Low today
$1.48
Low today$1.48
Open price
$1.50
Open price$1.50
Volume
15.99K
Volume15.99K
52 Week high
$88.40
52 Week high$88.40
52 Week low
$1.37
52 Week low$1.37

Stock Snapshot

Onconetix, Inc(ONCO) stock is priced at $1.56, giving the company a market capitalization of 2.43M. It carries a P/E multiple of -0.01.

On 2026-01-14, Onconetix, Inc(ONCO) stock traded between a low of $1.48 and a high of $1.56. Shares are currently priced at $1.56, which is +5.6% above the low and 0.0% below the high.

Onconetix, Inc(ONCO) shares are trading with a volume of 15.99K, against a daily average of 62.22K.

In the last year, Onconetix, Inc(ONCO) shares hit a 52-week high of $88.40 and a 52-week low of $1.37.

In the last year, Onconetix, Inc(ONCO) shares hit a 52-week high of $88.40 and a 52-week low of $1.37.

People also own

Based on the portfolios of people who own ONCO. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .